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Abstract
Despite the global decline in the incidence and mortality of gastric cancer, it remains one of the most common
malignant tumors of the digestive system. Although surgical resection is the preferred treatment for gastric cancer,
chemotherapy is the preferred treatment for recurrent and advanced gastric cancer patients who are not
candidates for reoperation. The short overall survival and lack of a standard chemotherapy regimen make it
important to identify novel treatment modalities for gastric cancer. Within the field of tumor biology, molecular
targeted therapy has attracted substantial attention to improve the specificity of anti-cancer efficacy and
significantly reduce non-selective resistance and toxicity. Multiple clinical studies have confirmed that molecular
targeted therapy acts on various mechanisms of gastric cancer, such as the regulation of epidermal growth factor,
angiogenesis, immuno-checkpoint blockade, the cell cycle, cell apoptosis, key enzymes, c-Met, mTOR signaling and
insulin-like growth factor receptors, to exert a stronger anti-tumor effect. An in-depth understanding of the
mechanisms that underlie molecular targeted therapies will provide new insights into gastric cancer treatment.
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Background
Gastric cancer is a common malignancy of the digestive
system and is the second most common cause of cancer-
related death [1]. Over 1,000,000 new cases occur each
year, of which more than 70 % are diagnosed in develop-
ing countries, particularly in East Asia [2]. Although sur-
gery is the primary method for gastric cancer treatment,
the majority of patients exhibit advanced disease at the
time of diagnosis, which limits the effectiveness of sur-
gery. Chemotherapy is appropriate for these patients.
However, the objective response rate is only 20–40 %,
and the median overall survival (OS) time is only 6–11
months following chemotherapy [3]. Moreover, the ser-
ious side effects of chemotherapy cannot be ignored.
As a result of the rapid advancements in the field of
tumor biology, attention has been focused on the new
modality of molecular targeted therapy for advanced
cancer. Molecular targeted inhibitors effectively regulate
overexpressed molecules in tumor cells and the signaling
pathways that are closely associated with tumorigenesis,
thereby modulating the biological behavior of tumor
cells [4]. Molecular targeted therapy not only improves
the specificity and selectivity of anti-cancer therapy but
also avoids non-selective toxicity and resistance. A sub-
stantial number of molecular targeted drugs have been
approved by the Food and Drug Administration (FDA)
for clinical use (Fig. 1). A comprehensive understanding
of the theoretical basis of molecular targeted therapy will
facilitate breakthroughs in the clinical treatment of gas-
tric cancer.
Agents that target epidermal growth factor
receptor (EGFR)
EGFR is a transmembrane glycoprotein that is composed
of 1186 amino acids. The EGFR family includes four
members: HER-l (EGFR), HER-2 (Neu), HER-3 and
HER-4. HER-2 and HER-3 bind to other EGFR family
members to form a heterodimer. For example, HER-2
binds EGFR, and the kinase activity of HER-2 subse-
quently phosphorylates the heterodimer, which leads to
phosphatidylinositol 3-kinase (PI3K)/Akt and Ras/MEK
signaling pathway activation [5]. These pathways pro-
mote cell proliferation, differentiation and invasion and
suppress apoptosis (Fig. 2). An abnormally high expres-
sion of EGFR and HER-2 has been identified in gastric
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Fig. 2 Mechanism of molecular targeted therapy in gastric cancer. Molecular targeted therapy acts on various mechanisms of gastric cancer, such as EGFR,
angiogenesis, PDGF, IGF-1R, key enzymes or c-Met, and thus activates related signaling pathways to promote cell proliferation, differentiation, invasion and
suppress apoptosis. Abbreviations: VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; IGF-1R, insulin-like
growth factor 1 receptor; FGFR, fibroblast growth factor receptor
Fig. 1 Molecular targeted agents approved by the FDA for different cancers. Abbreviations: CML, Ph + chronic myeloid leukemia; ALL,
lymphoblastic leukemia; NSCLC, non-small cell lung cancer; CLL, chronic lymphocytic leukemia
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cancer cells, colorectal cancer cells and esophageal squa-
mous cell carcinoma cells [6–8]. The expression levels
of HER-1 and HER-2 are positively correlated with the
depth of tumor invasion and negatively correlated with
the degree of tumor differentiation and survival dur-
ation. Therefore, drugs that target EGFR and HER-2 are
expected to improve the therapeutic efficacy of gastric
cancer treatments.
Anti-EGFR monoclonal antibodies
Cetuximab (Cetuximab, C225) is a humanized IgG1
monoclonal antibody that specifically binds to the extra-
cellular domain of EGFR. This antibody competitively
inhibits the binding of EGFR to its natural ligands and
blocks the ligand-induced phosphorylation of the tyro-
sine kinase domain of EGFR. Cetuximab downregulates
the expression of cell surface receptors and weakens
receptor-related signaling. Cetuximab also kills tumor
cells via antibody-dependent cellular cytotoxicity [9].
Since cetuximab was introduced to the market in 2004
[10], numerous phase II clinical studies have assessed
the efficacy and safety of its combination with other
chemotherapy regimens, including FOLFIRI, docetaxel/
cisplatin, FOLFOX, and XELOX [11–15]. These clinical
trials have identified a tumor response rate of 41.2–52.3
% and a median OS time of 5.4–16 months for patients
with advanced gastric cancer. Based on data from mul-
tiple studies, there is no significant difference in the re-
sults between first-line treatment with a combination
treatment of cetuximab and other chemotherapy regi-
mens and the use of a single-agent chemotherapeutic
regimen; however, the former treatment represents an
alternative choice for first-line treatment because of its
relatively lower toxicity. As a second-line treatment,
combination regimens including cetuximab are clearly
advantageous in terms of reduced toxicity. However,
whether this regimen can be regarded as the standard
regimen depends on economic factors. Many Phase II
and III clinical trials to investigate the effects of combin-
ation regimens including cetuximab are ongoing [16].
Cetuximab in combination with capecitabine and cis-
platin in advanced esophagogastric cancer (EXPAND), a
phase III clinical trial, evaluated the efficacy of cetuxi-
mab in combination with capecitabine and cisplatin as a
first-line treatment for advanced gastric cancer [17].
However, no significant difference in the median OS
time or median progression-free survival (PFS) was iden-
tified between the experimental and control groups (4.4
vs 5.6 months, respectively, p = 0.32 and 9.4 vs
10.7 months, p = 0.95, respectively), although the inci-
dence of adverse reactions was increased in the experi-
mental group compared with the control group.
Multivariate analysis indicated that mutations in the Kir-
sten rat sarcoma viral oncogene homolog (KRAS) and
PIK3CA were poor prognostic factors. In colon cancer,
the efficacy of cetuximab was increased in patients who
carried wild-type KRAS; patients who carried the mutant
KRAS were resistant to cetuximab treatment. However,
the relationship between KRAS expression and treat-
ment efficacy in gastric cancer patients has not been
established.
In contrast to cetuximab, panitumumab is a com-
pletely humanized monoclonal antibody. Panitumumab
is beneficial for colorectal cancer patients who have
failed FOLFOX treatment. In REAL3, a phase II/III clin-
ical trial, treatment with panitumumab combined with
modified epirubicin, oxaliplatin, and capecitabine did
not improve the condition of patients with esophageal,
gastroesophageal junction or gastric cancer or with un-
differentiated carcinoma [18]. The median OS time
using this regimen was significantly shorter than the
standard regimen of epirubicin, oxaliplatin, and platinum
(median OS time of 11.3 months); furthermore, the me-
dian PFS was shorter in the experimental group com-
pared with the control group (6.0 vs 7.4 months,
respectively, p = 0.068). The tendency toward shorter
survival may have been a result of inadequate chemo-
therapy drug doses, accelerated cancer progression after
drug withdrawal or an inability to continue therapy be-
cause of the deterioration of the host’s condition. The
failure of the EXPAND and REAL3 trials suggested that
EGFR may not be the primary oncogenic driver in ad-
vanced gastric cancer. Therefore, the identification of
predictive markers of anti-EGFR treatment outcome to
determine the population that would most likely benefit
from this therapy is crucial for therapeutic efficacy.
Anti-HER-2 monoclonal antibodies
Trastuzumab is a recombinant, humanized IgG1 mono-
clonal antibody that binds to the HER-2 receptor to
eliminate or reduce receptor activity, which thereby
weakens subsequent signaling events that involve mole-
cules such as protein kinase B (PKB) and signal trans-
ducer and activator of transcription 3 (STAT3). In
addition, trastuzumab induces antibody-dependent cyto-
toxicity by increasing the expression of the cyclin-
dependent kinase (CDK) inhibitor p27, which causes the
downregulation of cell cycle proteins and cell cycle dis-
orders [19]. The outcomes of the ToGA trial by Bang
et al. [20] comprised the initial evidence to demonstrate
that combination chemotherapy with trastuzumab im-
proves the survival rate of HER-2-positive advanced gas-
tric cancer patients. The study defines the standard for
HER-2 positive as “+++” via immunohistochemistry
(IHC) or “+” via fluorescence in situ hybridization
(FISH). The high expression of HER-2 was IHC (+++) or
IHC (++) and FISH (+), and the low expression of
HER-2 was FISH (+) and IHC (− or +). Overall, 584
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cases were included and randomly divided into two
groups based on treatment with trastuzumab plus
chemotherapy (294 cases) and chemotherapy (290
cases). The results demonstrated that the efficacy end-
point in the trastuzumab plus chemotherapy group sig-
nificantly improved: 47 vs 35 %, respectively, for total
efficiency (p = 0.0017); 13.8 vs 11.1 months, respectively,
for the median OS time (p = 0.0046); and 6.7 vs
5.5 months, respectively, for PFS (p = 0.0002). Further
analysis indicated that in the 446 cases with high expres-
sion of HER-2, the median OS time was significantly in-
creased in the trastuzumab plus chemotherapy
compared with the chemotherapy group (16.0 vs
11.8 months, respectively). This trial prolonged the OS
of patients beyond one year, and the quality of life of the
patients with advanced gastric cancer was greatly im-
proved. These findings highlight the advantages of indi-
vidualized treatment. Despite such impressive results,
many noteworthy issues in clinical applications remain
considering the results of the subgroup analysis: only pa-
tients with IHC (+++) or IHC (++)/FISH (+) benefitted
from the combination therapy, while the cases of IHC
(−) or IHC (+)/FISH (+) did not show benefits. Further-
more, the combination was only effective for intestinal
gastric cancer. There was no significant difference in
Asian patients between the two groups. Given the evi-
dence regarding the first-line treatment, the European
Medicines Agency (EMA) and the U.S. FDA approved
trastuzumab combined with either capecitabine or 5-FU
and DDP to treat metastatic gastric cancer or gastro-
esophageal junction cancer in 2010. Furthermore, the
HELOISE trial is investigating the optimal dose of tras-
tuzumab in these patients.
Pertuzumab is a recombinant humanized monoclonal
antibody that binds to the extracellular domain of HER-
2 and directly suppresses the dimerization of HER-2,
which thereby inhibits downstream signaling pathways.
The primary difference between pertuzumab and trastu-
zumab is that the trastuzumab-induced inhibition of
ligand-induced dimerization is dependent on HER-2 ex-
pression levels, which suggests that a broader range of
individuals will benefit from pertuzumab [21]. To date,
there are no clinical reports regarding the use of pertu-
zumab in the treatment of gastric cancer. However, a
preclinical study demonstrated that pertuzumab com-
bined with trastuzumab enhanced the anticancer effect
in an HER2-positive gastric cancer xenograft model [22].
A double-blind, placebo-controlled, randomized clinical
study, JACOB, is ongoing to evaluate the efficacy and
safety of pertuzumab combined with trastuzumab and
cisplatin and 5-FU/capecitabine treatment in HER2-
positive metastatic gastric cancer or gastroesophageal
junction cancer [23]. The study is expected to include
780 patients from 35 countries.
Tyrosine kinase inhibitors (TKIs) of EGFR/HER-2
TKIs competitively antagonize the binding of ATP to a
TKD, which thus inhibits the autophosphorylation of re-
ceptor tyrosine kinases and blocks the activation of
EGFR-mediated signaling pathways, ultimately leading to
the inhibition of tumor cell proliferation. TKIs provide
more apparent benefits to patients with mutant EGFR
compared with patients with translocated wild-type
EGFR [24]. Gefitinib was the first TKI used to treat can-
cer. Gefitinib exhibits biological activity in tumor cells
and increases the sensitivity of these cells to radiation
[25]. However, the efficacy of gefitinib in the treatment
of gastroesophageal junction adenocarcinoma is not
ideal [26]. This limited efficacy may result from rare
EGFR mutations, particularly gefitinib-related mutations,
such as delE746-A750 or L858R, in esophagogastric
junction adenocarcinoma [27]. Therefore, gefitinib is not
primarily recommended for gastric cancer treatment.
Erlotinib (Tarceva) is another small-molecule tyrosin-
ase inhibitor. The Southwest Cancer Cooperative Group
conducted a phase II clinical trial (SWOG 0127) and re-
ported the effectiveness of erlotinib for the treatment of
gastroesophageal junction adenocarcinoma [28].
In addition, several tyrosinase inhibitors, such as lapa-
tinib, target both EGFR and HER-2. These inhibitors not
only prevent the autophosphorylation and activation of
these receptors in tumor cells but also bind to EGFR or
HER-2 dimers to inhibit downstream signaling pathways
[29]. TRIO-013/(LOGiC), a phase III clinical trial, com-
pared the efficacy of capecitabine and oxaliplatin with
and without lapatinib to treat HER-2-positive advanced
gastric, esophageal junction and gastroesophageal can-
cers [30]. Lapatinib did not significantly improve the
median OS time compared with chemotherapy alone.
Despite the increase in the median OS time and the ob-
jective response rate in the experimental group com-
pared with the control group, the incidence of diarrhea
and skin toxicity was substantially higher in the former
compared with the latter group. However, a subgroup
analysis indicated that patients <60 years of age and
Asian patients greatly benefited from the addition of
lapatinib. Another phase III clinical trial, TyTAN, deter-
mined that lapatinib combined with paclitaxel as a
second-line regimen for advanced gastric cancer in pa-
tients who exhibited amplification of HER-2 (FISH-posi-
tive) did not significantly alter the median OS time (11
vs 8.9 months, respectively) or the mean PFS compared
with paclitaxel alone (5.4 vs 4.4 months, respectively)
[31]. TyTAN demonstrated that lapatinib prolonged the
survival of patients who received this second-line treat-
ment for advanced gastric cancer; however, this conclu-
sion was specific to HER-2-positive patients. The
efficacy of lapatinib for gastric cancer may not be as
beneficial as trastuzumab. This discrepancy may be
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attributed to individual differences in drug metabolism
and bioavailability, as well as lapatinib-related treatment
resistance. Studies have demonstrated that lapatinib re-
sistance may be associated with secondary HER-2 muta-
tions, MET overexpression, and PTEN deletion [32–34].
However, in mainland China, patients exhibited an in-
creased median OS time and median PFS when adminis-
tered lapatinib and paclitaxel compared with paclitaxel
alone [31]. The subgroup analysis demonstrated that
lapatinib may provide a survival benefit to Chinese pa-
tients. Thus, additional prospective studies of Asian pa-
tients with HER-2-positive advanced gastric cancer are
warranted.
Agents that target vascular endothelial growth
factor (VEGF)
Cancer is a vascular-dependent disease. When the tumor
volume reaches 2 mm3, the tumor cells become hypoxic
and secrete a broad range of factors to promote tumor
angiogenesis, growth and invasion. Therefore, interven-
tions that target tumor angiogenesis have become a pri-
mary strategy for cancer therapy.
VEGF is one of the most important cytokines in the
induction of tumor angiogenesis. VEGF induces tumor
angiogenesis by promoting endothelial cell proliferation
and increasing vascular permeability. VEGF expression
is commonly high in gastric cancer tissues and is related
to the invasiveness, clinical stage and prognosis of gas-
tric cancer [35]. Anti-VEGF antibodies and VEGF inhibi-
tors are expected to block angiogenesis and downstream
signaling, which thereby decrease tumor blood flow and
nutrient supply and increase vascular permeability to
promote drug penetration into the tumor.
Anti-VEGF monoclonal antibodies
Bevacizumab is a humanized anti-VEGF monoclonal
antibody that specifically binds VEGF, which inhibits the
binding of VEGF to the VEGF receptor (VEGFR) and
blocks the activation of tyrosine kinase signaling path-
ways. These effects suppress the proliferation of endo-
thelial cells and inhibit angiogenesis. Humanization is
beneficial for extending the half-life and reducing the
immunogenicity of a therapeutic antibody. Bevacizumab,
which highly specifically recognizes and binds to VEGF,
was the first FDA-approved anti-VEGF monoclonal anti-
body for cancer treatment. It has been acknowledged for
clinical use to treat colorectal cancer, non-small cell lung
cancer (NSCLC), breast cancer, renal cell carcinoma,
ovarian cancer and glioblastoma [36–44]. To assess its
value as a first-line treatment for late-stage gastric can-
cer, a randomized, double-blind phase III clinical trial,
referred to as the AVAGAST Study, was conducted. In
this study, the OS increased from 10.1–12.1 months in
the control group, the median PFS increased from 5.3 –
6.7 months, and the overall response rate improved (37
vs 46 %, respectively); however, these differences were
not significant [45]. Adverse reactions to bevacizumab,
such as embolic disease and gastric perforation, should
not be overlooked [46]. Van Cutsem et al. [47] evaluated
whether angiogenesis markers predicted the effects of
bevacizumab and determined that the efficacy of bevaci-
zumab was related to the baseline expression of VEGF-
A and Neuropilin-1. In a non-Asian population, the me-
dian OS time was longer in patients with a high level of
VEGF-A expression and a low level of Neuropilin-1 ex-
pression. These findings suggest that the future develop-
ment of gastrointestinal cancer treatments must include
the identification of appropriate biomarkers for individu-
alized treatment.
Anti-VEGFR monoclonal antibodies
Ramucirumab is a completely humanized monoclonal
antibody against VEGFR. A randomized phase III study
of advanced gastric cancer patients who had failed first-
line treatment demonstrated that best supportive care
plus ramucirumab significantly improved the OS, PFS,
and disease control rate compared with the control
group [48]. Another phase III clinical study demon-
strated that the combination of ramucirumab and
chemotherapy markedly increased the OS, PFS and dis-
ease control rate for advanced gastric cancer [49].
Therefore, based on the results of these two important
phase III clinical trials, the EMA and the U.S. FDA ap-
proved ramucirumab as the second-line therapy for gas-
troesophageal junction and chemotherapy-failed gastric
adenocarcinomas, either alone or in combination with
paclitaxel, in 2014. However, its primary adverse reac-
tions, such as neutropenia, leukopenia, hypertension and
decreased strength, cannot be ignored.
TKIs
Sunitinib is an oral multi-targeted TKI. Its mechanism
of action involves the inhibition of the tyrosine kinase
activity of VEGF, platelet-derived growth factor receptor-
β, KIT (stem cell factor receptor), FMS-like tyrosine
kinase-3 receptor (FLT-3) and rearranged during trans-
fection (RET); it consequently specifically blocks signal
transduction associated with these kinases to exert anti-
tumor effects. In a phase II clinical study, the combin-
ation of sunitinib and docetaxel improved the objective
remission rate (41.1 vs 14.3 %, respectively) in patients
with metastatic gastric cancer compared with docetaxel
alone [50]. Various phase І and II clinical trials have con-
firmed the safety and tolerability of sunitinib combined
with traditional chemotherapies; however, it clinical sig-
nificance requires further investigation in randomized
controlled trials [50–52]. Sorafenib is another multi-
targeted TKI. Sorafenib directly suppresses the Raf-
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MEK-ERK signaling pathway and indirectly reduces
VEGFR activity, which thus inhibits tumor growth. So-
rafenib is beneficial for more than 20 types of malignant
cancer and is associated with few side effects. A phase II
clinical trial that included 44 patients with advanced gas-
tric cancer indicated that sorafenib combined with doce-
taxel and cisplatin was associated with a 5.8 month
median PFS and a 13.6 month median OS time [53].
Phase П clinical trials regarding the efficacy of orafenib
combined with oxaliplatin and capecitabine are ongoing.
Additional clinical trials are necessary to determine the
efficacy of these anti-VEGF TKIs in the treatment of ad-
vanced gastric cancer.
Immuno-checkpoint blockade
The development of a monoclonal antibody targeting
immuno-checkpoints has attracted substantial attention
in recent years. It can induce sustained tumor remission
and is effective in treating various tumors. Immuno-
checkpoints are inhibitory signaling pathways in the im-
mune system that not only regulate the sustainability
and strength of the immune response in peripheral tis-
sue to avoid tissue damage but are also involved in
maintaining tolerance to self-antigens. Targeting these
inhibitory signaling pathways to inhibit T cell activity is
a key mechanism to avoid tumor escape from immuno-
logic cytotoxicity. Monoclonal antibodies targeted at
PD-1, PD-L1 and CTLA-4 have been gradually imple-
mented in clinical research. Moreover, the synergistic ef-
fects of various immunosuppressors are expected to
represent an effective treatment mode. Duraiswamy et
al. used PD-1 and CTLA-4 antibodies to block multiple
immuno-checkpoints, which led to the enhancement of
T cell reactivity. In the near future, a combined antibody
targeted at PD-1, PD-L1 and CTLA-4 will be developed
for the treatment of gastric cancer [54].
Agents that act on the tumor cell cycle
Cancer is a disorder of cell cycle regulatory mechanisms.
There are three main types of molecules involved in cell
cycle regulation: cyclins, CDKs and CDK inhibitors
(CKIs). CDKs bind to cyclins, which facilitates the cross-
ing of restriction points by cells during cell cycle pro-
gression. CDKs also combine with CKIs to inhibit cell
cycle progression or induce apoptosis [55]. Therefore,
CKIs likely induce cell cycle arrest at certain phases.
Flavopiridol is a semi-synthetic flavonoid CKI and was
the first cell cycle inhibitor evaluated in a clinical trial.
Flavopiridol extensively suppresses messenger RNA
translation by blocking the transport of transcripts to
ribosomes, which leads to the cessation of cell
proliferation-related protein expression [56]. However,
flavopiridol failed to exert the desired effect on gastric
cancer as a result of low efficacy and serious adverse
reactions [57]. Considering its poor anti-tumor activity
as a single agent, further investigation of its use com-
bined with other chemotherapeutic agents is necessary.
Agents that act on tumor cell apoptosis
Tumor cells are typically characterized by enhanced pro-
liferation, impaired differentiation and inhibited apop-
tosis. Consequently, the promotion of apoptosis is an
important topic in cancer therapy. Tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) select-
ively induces the apoptosis of multiple types of tumor
cells. Gastric cancer cells often exhibit resistance to
TRAIL-induced apoptosis; however, various chemothera-
peutic agents enhance the sensitivity of gastric cancer
cells to TRAIL [58]. Therefore, there is a potentially sub-
stantial benefit to combining TRAIL with chemother-
apies for the treatment of gastric cancer.
NF-κB belongs to the NF-κB/Rel protein family. NF-κB
expression positively correlates with the degree of malig-
nancy and negatively correlates with cancer prognosis. Bor-
tezomib, a proteasome inhibitor, specifically inhibits the
chymotrypsin activity of the 26S proteasome, which thereby
inhibits the activation of the NF-κB signaling pathway. A
phase II study demonstrated that the bortezomib treatment
efficacy was 66 %, which suggests that bortezomib is a feas-
ible option for relapsed/refractory cancer [59].
Progress in other related fields
Matrix metalloproteinase (MMP) inhibitors
MMPs include a series of proteolytic enzymes that par-
ticipate in the degradation and destruction of the extra-
cellular matrix and the basement membrane. The
abnormal expression of MMPs promotes local tumor in-
vasion and spread. High expression of MMP-2, MMP-9,
MMP-14 and MMP-21 is associated with the progres-
sion and poor prognosis of gastric cancer [60–63]. The
MMP inhibitor marimastat (BB-2516, TA-2516) exhibits
anti-tumor activity in gastric cancer. Advanced gastric
cancer patients also benefit from marimastat because of
its low hematological toxicity, which confirms the clin-
ical value of marimastat for gastric cancer patients [64].
c-Met signaling pathway inhibitors
c-Met is a membrane receptor tyrosine kinase capable of
binding to HGF and activating the HGF/c-Met signaling
pathway, which thereby regulates the proliferation and
migration of tumor cells [65]. Furthermore, HGF/c-Met
signaling may block the activation of β4-integrin, CD44
and non-kinase molecules, which are closely related to
an enhanced capacity for invasion and angiogenesis [66].
Because of its position at the intersection of multiple
signaling pathways that are closely related to tumor for-
mation and metastasis, c-Met has become a promising
new target as modifying its activity may simultaneously
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interfere with all relevant pathways [67]. c-Met overex-
pression has been observed in gastric cancer patients
[68]. A phase II clinical trial demonstrated that a com-
bination regimen that contained rilotumumab, a c-Met
inhibitor, provided a survival benefit [69]. Currently, the
efficacy of rilotumumab has been demonstrated for c-
Met-positive gastric cancer or esophagogastric junction
cancer in RILOMET-1, a phase III clinical study [70].
Foretinib is a new type of inhibitor of c-Met and
VEGFR2/KDR. In 2009, Kwak et al. reported good
efficacy and safety of foretinib in a phase I clinical
study at an ASCO meeting [71]. Based on reliable
evidence, the FDA approved the drug to directly enter
phase III trials for the treatment of NSCLC without a
phase II trial. However, few studies have investigated
the use of foretinib in gastric cancer; thus, further re-
search is necessary.
Therapies targeting mTOR
mTOR belongs to the PI3K-related kinase family, which
primarily regulates cell growth, cell proliferation, the cell
cycle, and other physiological functions via the PI3K/
Akt/mTOR signaling pathway [72]. The expression of
phosphorylated mTOR is a prognostic factor for gastric
cancer that negatively correlates with cancer prognosis
[73]. Everolimus prevents the phosphorylation of
p70S6K and 4E-BP1 mediated by mTOR, which results
in G0/G1 arrest [74]. However, a phase III clinical study
of everolimus in advanced gastric cancer patients who
failed previous chemotherapy treatment demonstrated
that there was no significant efficacy of everolimus in
gastric cancer [75].
Cyclooxygenase-2 (COX-2) inhibitors
COX is an important rate-limiting enzyme in the con-
version of arachidonic acid to prostaglandins. COX-1
and COX-2 are two COX isoenzymes. COX-2 is barely
expressed under physiological conditions; however, it is
highly expressed in gastric cancer. COX-2 is involved
in tumorigenesis and cancer development via the pro-
motion of cell proliferation, suppression of apoptosis,
and induction of tumor angiogenesis. COX-2 inhibitors
have been demonstrated to exert anti-cancer effects on
gastric cancer cells; however, precise clinical trial data
are lacking [76]. Importantly, the gastrointestinal adverse
effects of COX inhibitors limit their widespread clinical
application.
Insulin-like growth factor receptor (IGF-IR) inhibitors
IGF-IR is a transmembrane tyrosine kinase receptor,
which is activated after binding to IGF-1 and IGF-2.
IGF-IR plays a key role in malignant transformation,
Table 1 Characteristic of molecular targeted agents for gastric cancer treatment
Agent Type Target(s) Current prospects for gastric cancer therapy
Trastuzumab Recombinant humanized mAb HER-2 Approved by FDA
Ramucirumab Humanized mAb VEGFR Approved by FDA
Sorafenib Tyrosine kinase inhibitor VEGF, PDGF Phase II or III clinical trials are ongoing
Marimastat Inhibitor MMPs Phase II or III clinical trials are ongoing
Erlotinib Tyrosine kinase inhibitor EGFR Phase II clinical trials are ongoing
Foretinib Inhibitor c-Met, KDR VEGFR2 Clinical trials are ongoing
Bevacizumab Humanized mAb VEGF Individualized treatment [47]
Pertuzumab Recombinant humanized mAb HER-2 A Phase III clinical trial is ongoing [23]
Sunitinib Tyrosine kinase inhibitor VEGF, PDGF, KIT, FLT-3, RET Promising [50-52]
Bortezomib Proteasome inhibitor NF-κB Promising [59]
Rilotumumab Inhibitor c-Met Promising [69]
Everolimus Inhibitor mTOR Not satisfactory [75]
Lapatinib Tyrosine kinase inhibitor EGFR, HER-2 Satisfactory for a specific population [30, 31]
Gefitinib Tyrosine kinase inhibitor EFGR Limited efficacy [26]
Cetuximab Humanized mAb EFGR Not satisfactory [17]
Panitumumab Humanized mAb EFGR Not satisfactory
Flavopiridol Semi-synthetic flavonoid inhibitor CDK Not satisfactory (Phase II clinical trial failed)
Figitumumab Humanized mAb IGFR-IR Phase I clinical trials are ongoing
Abbreviations: mAb monoclonal antibody, EGF epidermal growth factor, EGFR epidermal growth factor receptor, FDA Food and Drug Administration, MMP matrix
metalloproteinase, VEGF vascular endothelial growth factor, PDGF platelet-derived growth factor, RET rearranged during transfection, FLT3 FMS-like tyrosine
kinase-3 receptor, CDK cyclin-dependent kinase
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angiogenesis, metastasis, and anti-apoptosis. Figitumu-
mab (CP-751871) is a completely humanized IgG2
monoclonal antibody against IGF-IR. Phase І and II clin-
ical studies have confirmed the efficacy of figitumumab
on Ewing’s sarcoma and NSCLC; however, a phase Ш
clinical study of NSCLC was terminated halfway due to
no reaching the endpoint [77–79]. Studies of this agent
in gastric cancer treatment are in the clinical research
stage.
Conclusions and challenges
Although an increasing number of clinical studies has
explored effect of targeted therapy alone or in combin-
ation with chemotherapy in the field of gastric cancer
(Tables 1 and 2), its application in gastric cancer remains
in its infancy compared with its successful use in colon,
lung, and breast cancers. Targeted therapy for gastric
cancer continues to face enormous challenges (Fig. 3)
(1). Numerous phase II clinical trials have been per-
formed; however, precise Phase III clinical trials are lack-
ing. Additional in-depth Phase III clinical studies must
be pursued to obtain sufficient evidence to support the
use of targeted therapy for gastric cancer. (2) Targeting a
single molecule has limited use for the treatment of gas-
tric cancer because of the complex pathogenesis of the
disease. Consequently, drugs that target a single mol-
ecule will be susceptible to a loss of efficacy soon after
compensatory mechanism activation. Furthermore, it is
difficult to target the entire tumor because subclones of
gastric cancer cells exhibit different biological behaviors.
This is only one of the primary reasons for the failure of
single agents as a broad treatment for gastric cancer.
Therefore, the development of multi-target drugs or the
combination of targeted drugs with surgery, radiotherapy
and chemotherapy may result in new opportunities for
cancer treatment. (3) Individual differences create
Table 2 Evaluation of combination chemotherapy for gastric cancer treatment
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challenges; not all patients benefit from a new treatment
modality. The detection of specific biomarkers or related
genes will be required to develop individualized treatment.
(4) The cost of targeted drugs remains one of the greatest
obstacles to their widespread use in clinical practice and
must decrease. Despite these challenges, we believe that
an in-depth understanding of the molecular mechanisms
that underlie tumor development will lead to break-
throughs in the targeted treatment of gastric cancer,
thereby opening a new chapter for advanced gastric
cancer.
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